Abstract
Thirty patients with Parkinson's disease were treated for four weeks with levodopa combined with an inhibitor of extracerebral dopa decarboxylase, L-alpha-methyldopahydrazine (MK 486). The therapeutic results were compared with the effects of treatment of a group of 40 patients with levodopa alone. Patients treated with the combined therapy improved more rapidly, had less nausea and vomiting, and required a much smaller dose of levodopa than patients treated with levodopa by itself.
Full text
PDF
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Barbeau A., Gillo-Joffroy L., Mars H. Treatment of Parkinson's disease with levodopa and Ro 4-4602. Clin Pharmacol Ther. 1971 Mar-Apr;12(2):353–359. doi: 10.1002/cpt1971122part2353. [DOI] [PubMed] [Google Scholar]
- Bartholini G., Burkard W. P., Pletscher A. Increase of cerebral catecholamines caused by 3,4-dihydroxyphenylalanine after inhibition of peripheral decarboxylase. Nature. 1967 Aug 19;215(5103):852–853. doi: 10.1038/215852b0. [DOI] [PubMed] [Google Scholar]
- Birkmayer W. Experimentelle Ergebnisse über die Kombinationsbehandlung des Parkinson-Syndroms mit L-DOPA und einem Decarboxylasehemmer (Ro 4-4602) Wien Klin Wochenschr. 1969 Sep 26;81(39):677–679. [PubMed] [Google Scholar]
- Calne D. B., Reid J. L., Vakil S. D., Rao S., Petrie A., Pallis C. A., Gawler J., Thomas P. K., Hilson A. Idiopathic Parkinsonism treated with an extracerebral decarboxylase inhibitor in combination with levodopa. Br Med J. 1971 Sep 25;3(5777):729–732. doi: 10.1136/bmj.3.5777.729. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cotzias G. C., Papavasiliou P. S., Gellene R. Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969 Feb 13;280(7):337–345. doi: 10.1056/NEJM196902132800701. [DOI] [PubMed] [Google Scholar]
- PORTER C. C., WATSON L. S., TITUS D. C., TOTARO J. A., BYER S. S. Inhibition of DOPA decarboxylase by the hydrazino analog of alpha-methylDOPA. Biochem Pharmacol. 1962 Nov;11:1067–1077. doi: 10.1016/0006-2952(62)90166-1. [DOI] [PubMed] [Google Scholar]
- Parkes J. D., Baxter R. C., Curzon G., Knill-Jones R. P., Knott P. J., Marsden C. D., Tattersall R., Vollum D. Treatment of Parkinson's disease with amantadine and levodopa. A one-year study. Lancet. 1971 May 29;1(7709):1083–1086. doi: 10.1016/s0140-6736(71)91834-4. [DOI] [PubMed] [Google Scholar]
- Tissot R., Gaillard J. M., Guggisberg M., Gauthier G., de Ajuriaguerra J. Thérapeutique du syndrome de Parkinson par la L-Dopa "per os" associée à un inhibiteur de la décarbosylase (Ro IV 46.02) Presse Med. 1969 Apr 5;77(17):619–622. [PubMed] [Google Scholar]
- Udenfriend S., Zaltzman-Nirenberg P., Gordon R., Spector S. Evaluation of the biochemical effects produced in vivo by inhibitors of the three enzymes involved in norepinephrine biosynthesis. Mol Pharmacol. 1966 Mar;2(2):95–105. [PubMed] [Google Scholar]
- Vesell E. S., Ng L., Passananti G. T., Chase T. N. Inhibition of drug metabolism by levodopa in combination with a dopa-decarboxylase inhibitor. Lancet. 1971 Aug 14;2(7720):370–370. doi: 10.1016/s0140-6736(71)90081-x. [DOI] [PubMed] [Google Scholar]
- Watanabe A. M., Chase T. N., Cardon P. V. Effect of L-dopa alone and in combination with an extracerebral decarboxylase inhibitor on blood pressure and some cardiovascular reflexes. Clin Pharmacol Ther. 1970 Sep-Oct;11(5):740–746. doi: 10.1002/cpt1970115740. [DOI] [PubMed] [Google Scholar]
- Yahr M. D., Duvoisin R. C., Mendoza M. R., Schear M. J., Barrett R. E. Modification of L-dopa therapy of Parkinsonism by alpha-methyldopa hydrazine (MK-486). Trans Am Neurol Assoc. 1971;96:55–58. [PubMed] [Google Scholar]